30 秒でわかる
Priscilla Chan argues that rare diseases may be overlooked by research strategies focused on large populations. She suggests broader access to tools could support more targeted research; SMA already has active research and approved treatments.
- 1A long tailCommon disease categories contain many distinct subtypes, alongside rare diseases.
- 2Broader accessChan argues for giving more researchers tools to pursue neglected questions.
- 3SMA contextSMA has active research and approved treatments.
ポイント
- Disease categories include many subtypes.
- Rare diseases can receive less attention in population-focused research.
- Chan favors broader access to research tools.
- SMA already has approved treatments.
チャプターごとに整えた全文を読む
Researching the long tail
Priscilla Chan argues that disease categories contain many subtypes, and that rare conditions may receive less attention when research focuses on interventions affecting the largest numbers of people.
Priscilla Chan argues that disease categories contain many subtypes, and that rare conditions may receive less attention when research focuses on interventions affecting the largest numbers of people.
She proposes putting research tools in more people’s hands so that individuals and smaller groups can pursue conditions they care about. As an example, she mentions spinal muscular atrophy (SMA).
Chan suggests that studying a rare disease can also reveal broader biological mechanisms. This is an argument for widening research participation, not a guarantee that a particular tool or project will produce a treatment.
SMA is already the subject of active research and has approved treatments; it should not be understood from the clip’s headline as a disease nobody studies. For example, the FDA has approved gene therapy for specified SMA patients. [FDA announcement](https://www.fda.gov/news-events/press-announcements/fda-approves-gene-therapy-treatment-spinal-muscular-atrophy).
同じチャンネルの記事
38:06EN
No Priors: AI, Machine Learning, Tech, & Startups· 2026年10月29日ポッドキャスト · 3 人Serval’s Jake Stauch on coding agents for enterprise ITゲスト Jake Stauch · ホスト Sarah Guo, Elad GilStauch explains why Serval is challenging ServiceNow, how it approaches permissions and approvals, and why background agents remain difficult to deploy safely.
39:23ENNo Priors: AI, Machine Learning, Tech, & Startups· 2026年10月15日ポッドキャスト · 2 人The Defenders' Window: Greg Brockman on AI-Generated Knowledge, Drug Discovery, and the New Physics of Cybersecurityホスト Sarah Guo, Elad GilOpenAI's president explains why solving open math problems is a proof point for science, how proactive agents change product form, and why security spending must exceed software spending.
1:09:44ENNo Priors: AI, Machine Learning, Tech, & Startups· 2026年10月9日ポッドキャスト · 2 人10,000 GB300s for Four Weeks: Reflection’s Open-Model Ledgerホスト Sarah Guo, Elad GilMisha Laskin tells No Priors how Reflection trained Beam, why reinforcement learning outspent pre-training, and why the West needs its own open weights.
35:39ENNo Priors: AI, Machine Learning, Tech, & Startups· 2026年10月2日ポッドキャスト · 2 人Compute Scaled a Millionfold. Bandwidth Only 40x. Fractile Wants to Fix That Ratioホスト Sarah Guo, Elad GilIn the summer of 2022, Walter Goodwin founded Fractile in London to build very fast inference chips for the world's largest models.
42:44ENNo Priors: AI, Machine Learning, Tech, & Startups· 2026年9月24日ポッドキャスト · 2 人They Paid $7.7 Billion for a Broker — and Intend to Do One Deal a Yearホスト Sarah Guo, Elad GilSequence Holdings co-founder Michael Lee tells No Priors why owning a market leader, not selling it software, is how AI actually remakes an incumbent.
38:14ENNo Priors: AI, Machine Learning, Tech, & Startups· 2026年9月18日ポッドキャスト · 2 人Diffusion Will Win Inference: Stefano Ermon Bets Parallel Tokens Beat Custom Siliconホスト Sarah Guo, Elad GilThe Stanford diffusion pioneer tells No Priors why a 50-person lab is training language models that generate many tokens at once — and why that maps to GPUs the way transformers once mapped to training.